Targeting pax2 for the treatment of breast cancer
AssigneePhigenix, Inc.
InventorCarlton D. DONALD
Life of this patent
Estimating the term…
Abstract
The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
Claims24
A method for treating a breast condition in a subject, comprising administering to the subject, an effective amount of a composition that inhibits PAX2 expression and/or PAX2 activity, and administering to the subject an effective amount of an anti-hormonal agent, wherein said composition comprises one or more ingredients selected from the group consisting of polynucleotides encoding an siRNA for PAX2, polynucleotides that inhibits binding of PAX2 to DEFB1 promoter, antagonists of angiotensin II, antagonists of angiotensin-converting enzyme (ACE), antagonists of mitogen-activated protein kinase (MEK), antagonists of extracellular signal-regulated kinase 1,2 (ERK1,2), antagonists of signal transducer, and blockers of the RAS signaling pathway.
3-13. (canceled)
A method for treating a breast condition in a subject, comprising:
- (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject;
- (b) determining the ER/PR status of said diseased breast tissue from said subject;
- and
- (c) based on the results of (a) and (b), administering to a breast tissue of said subject, a first composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1.
23-26. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.